CR9759A - Vacuna rotavirus que induce la proteccion cruzada heterotipica - Google Patents

Vacuna rotavirus que induce la proteccion cruzada heterotipica

Info

Publication number
CR9759A
CR9759A CR9759A CR9759A CR9759A CR 9759 A CR9759 A CR 9759A CR 9759 A CR9759 A CR 9759A CR 9759 A CR9759 A CR 9759A CR 9759 A CR9759 A CR 9759A
Authority
CR
Costa Rica
Prior art keywords
heterotipic
rotavirus vaccine
rotavirus
vaccine inducing
crossed
Prior art date
Application number
CR9759A
Other languages
English (en)
Inventor
Desiree Alberte Colau Brigitte
Arsen Virginie De Vos Beatrice
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516944A external-priority patent/GB0516944D0/en
Priority claimed from GB0521164A external-priority patent/GB0521164D0/en
Priority claimed from GB0608962A external-priority patent/GB0608962D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CR9759A publication Critical patent/CR9759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invencion proporciona un procedimiento de induccion de una respuesta inmune contra una cepa de rotavirus, comprendiendo el procedimiento la administracion a un sujeto de una composicion que comprende una cepa de rotavirus atenuado de un tipo GxPy, generando dicha composicion una respuesta inmune contra una cepa de rotavirus que ni es un tipo Gx ni Py.
CR9759A 2005-08-17 2008-02-22 Vacuna rotavirus que induce la proteccion cruzada heterotipica CR9759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0516944A GB0516944D0 (en) 2005-08-17 2005-08-17 Vaccine
GB0521164A GB0521164D0 (en) 2005-10-18 2005-10-18 Vaccine
GB0608962A GB0608962D0 (en) 2006-05-05 2006-05-05 Vaccine

Publications (1)

Publication Number Publication Date
CR9759A true CR9759A (es) 2008-05-05

Family

ID=37757924

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9759A CR9759A (es) 2005-08-17 2008-02-22 Vacuna rotavirus que induce la proteccion cruzada heterotipica

Country Status (25)

Country Link
US (1) US20090028828A1 (es)
EP (2) EP1915173A2 (es)
JP (1) JP5519934B2 (es)
KR (1) KR20080036648A (es)
AR (1) AR054916A1 (es)
AU (1) AU2006281566B2 (es)
BR (1) BRPI0615203A2 (es)
CA (1) CA2619751C (es)
CR (1) CR9759A (es)
CY (1) CY1116135T1 (es)
DK (1) DK2233153T3 (es)
EA (1) EA014328B1 (es)
ES (1) ES2534637T3 (es)
HR (1) HRP20150310T1 (es)
IL (1) IL189289A0 (es)
MA (1) MA29700B1 (es)
MX (1) MX2008002270A (es)
NO (1) NO20080754L (es)
PE (1) PE20070235A1 (es)
PL (1) PL2233153T3 (es)
PT (1) PT2233153E (es)
SG (1) SG163571A1 (es)
SI (1) SI2233153T1 (es)
TW (1) TW200740457A (es)
WO (1) WO2007020078A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
EP2197283B1 (en) * 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations for preservation of rota virus
US9311112B2 (en) * 2009-03-16 2016-04-12 Apple Inc. Event recognition
EP2701735A4 (en) * 2011-04-28 2014-11-26 Internat Medica Foundation LIQUID VACCINE COMPOSITIONS
CN104507495A (zh) * 2012-04-23 2015-04-08 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE170081T1 (de) * 1990-11-16 1998-09-15 Childrens Hosp Medical Center Humane rotativen, impfstoffe und methoden
AU767885B2 (en) * 1999-08-17 2003-11-27 Smithkline Beecham Biologicals (Sa) Vaccine
WO2005021033A2 (en) * 2003-09-02 2005-03-10 Glaxosmithkline Biologicals S.A. Vaccine

Also Published As

Publication number Publication date
MA29700B1 (fr) 2008-08-01
EP1915173A2 (en) 2008-04-30
AU2006281566A1 (en) 2007-02-22
PT2233153E (pt) 2015-04-20
TW200740457A (en) 2007-11-01
EP2233153B1 (en) 2015-01-21
PL2233153T3 (pl) 2015-06-30
NO20080754L (no) 2008-05-15
IL189289A0 (en) 2008-06-05
CY1116135T1 (el) 2017-02-08
ES2534637T3 (es) 2015-04-27
DK2233153T3 (da) 2015-04-27
CA2619751A1 (en) 2007-02-22
WO2007020078A3 (en) 2007-05-24
SI2233153T1 (sl) 2015-05-29
SG163571A1 (en) 2010-08-30
AU2006281566B2 (en) 2011-09-01
US20090028828A1 (en) 2009-01-29
JP5519934B2 (ja) 2014-06-11
KR20080036648A (ko) 2008-04-28
CA2619751C (en) 2016-07-05
EP2233153A1 (en) 2010-09-29
WO2007020078A2 (en) 2007-02-22
JP2009504701A (ja) 2009-02-05
AR054916A1 (es) 2007-07-25
PE20070235A1 (es) 2007-04-04
HRP20150310T1 (hr) 2015-06-19
EA200800320A1 (ru) 2008-10-30
MX2008002270A (es) 2008-03-27
EA014328B1 (ru) 2010-10-29
BRPI0615203A2 (pt) 2011-05-10

Similar Documents

Publication Publication Date Title
IN2012DN02736A (es)
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
ZA201805295B (en) Methods for enhancing efficacy of a vaccine by administering an il¿4r antagonist
CR9759A (es) Vacuna rotavirus que induce la proteccion cruzada heterotipica
DOP2016000298A (es) Pirazolopiridinas y pirazolopirimidinas
CL2011001810A1 (es) Cepa de saccharomyces cerevisiae; composicion fitosanitaria que la comprende; y procedimiento de tratamiento o proteccion de plantas contra enfermedades provocadas por agentes patogenos.
MX377288B (es) Composiciones sinérgicas que comprenden una cepa de bacillus subtilis y un pesticida.
ECSP077179A (es) Co-cultivos manejados de organismos que tienen efectos profilacticos y promotores de la salud
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
CO6160335A2 (es) Vacuna
CR10347A (es) Anticuerpos contra el peptidob-amiloide
TW200806316A (en) Yeast-based vaccine for inducing an immune response
MX2009003378A (es) Concentrados en suspension para la mejora de la absorcion por la raiz de principios activos agroquimicos.
BRPI0821240B8 (pt) formas mutantes de estreptolisina o
MA43650B1 (fr) Formulations/compositions comprenant un inhibiteur de btk
EA201400510A1 (ru) Водная фотозащитная композиция для личной гигиены
PH12015501875A1 (en) Acellular pertussis vaccine
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
TW200603825A (en) Prrsv subunit vaccines
MX2011006516A (es) Terapia de combinacion de virus de hepatitis c.
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
AR052639A1 (es) Composicion vacunal contra el virus de la hepatitis c.
MX2012002630A (es) Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul.
CR20110501A (es) Composiciones para la protección de cosechas, método para su aplicación y uso de dichas composiciones para protección de cosechas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)